适应风险的综合疗法在早期的异节性自然杀手/T细胞淋巴瘤:基于马尔科夫模型的成本效益分析
Jing Yang1, Qiu-Zi Zhong2, Li-Ting Qian3
1National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
JCO global oncology
|January 15, 2026
概括
组合疗法 (CMT) 对早期的外节自然杀手/T细胞淋巴瘤 (ENKTCL) 提供了生存益处,但对低风险患者来说不具有成本效益. 高风险患者显示CMT具有显著的成本效益.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
背景情况:
- 组合疗法 (CMT) 与单独放射治疗 (RT) 相比,在早期的外节自然杀手/T细胞淋巴瘤 (ENKTCL) 中改善了存活率.
- 然而,它对低风险患者的成本效益仍然不确定,根据名ogram修订风险指数 (NRI) 定义.
研究的目的:
- 评估CMT与单独RT在不同风险组的早期ENKTCL的成本效益.
- 为了确定CMT的生存益处是否超过了它对各种患者风险层的额外成本.
主要方法:
- 基于NRI的5个风险组,使用马尔科夫模型来比较单独的CMT和RT.
- 关于过渡概率,有效性和成本的数据来源于中国淋巴瘤协作小组队列.
- 医疗公用事业的负面影响估计,从中国付款人的角度进行分析.
主要成果:
- 在所有风险群体中,CMT增加了寿命,具有不同的增量成本效益比率 (ICER).
- 对于低风险 (NRI=0) 和中低风险 (NRI=1) 组,在5,208美元/QALY的支付意愿 (WTP) 门下,CMT的成本效益不佳.
- 高风险 (NRI=3) 和非常高风险 (NRI=4) 组表现出高概率 (72.07%和99.10%) 的成本效益,分别.
结论:
- 对于低风险的早期ENKTCL患者来说,CMT不太可能具有成本效益.
- 对于高风险和非常高风险患者来说,CMT很可能具有成本效益.
- 对于中等风险群体的成本效益取决于时间地平线和WTP值.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.7K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
3.8K
相关概念视频
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...